Progyny, Inc. Provides Earnings Guidance for the First Quarter Ending March 31, 2024 and Full Year Period Ending December 31, 2024
February 27, 2024 at 04:11 pm EST
Share
Progyny, Inc. provided earnings guidance for the first quarter ending March 31, 2024 and full year period ending December 31, 2024. For the first quarter ending March 31, 2024, Revenue is projected to be $285.0 million to $292.0 million, reflecting growth of 10% to 13% and Net income is projected to be $12.4 million to $13.7 million, or $0.12 to $0.13 per diluted share.
For the full year period ending December 31, 2024, Revenue is projected to be $1,285 million to $1,315 million, reflecting growth of 18% to 21% and Net income is projected to be $68.1 million to $73.6 million, or $0.66 to $0.71 per diluted share.
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Companyâs clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a memberâs full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
PROGYNY, INC. 
